Back to news

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Globe Newswire18/09/202608:05 ET
0

Get started

Create a free account to read the full story and Whiz Insights.

Sign Up

Already have an account? Log in